Anita Milicic studied Molecular Biology and Physiology at the University of Belgrade, Serbia, before completing MSc in Genetics and DPhil in Immunology at the University of Oxford. She joined the Jenner Institute in Oxford as the Head of the Adjuvant Facility, acquiring and testing a range of novel vaccine adjuvants for human and veterinary applications, leading to the selection of Matrix M as the choice adjuvant for the R21 malaria vaccine.
  The Vaccine Formulation and Adjuvants Group is focused on exploring immune mechanisms of vaccines and adjuvants, and developing novel vaccine formulations and delivery modalities. Anita's research interest is in understanding the processes that underpin the immune response to vaccination, in particular the interplay between innate and adaptive immunity. This is studied through modulating the context (vaccine modality) and the kinetics of antigen delivery, employing a combination of in vitro and in vivo animal model systems and human in vitro and ex vivo studies.
  Apart from research, Anita is involved in teaching at Oxford and internationally, and writing popular science articles on vaccination and vaccine adjuvants.
  Anita is the Jenner Institute Director of Graduate Studies and the Lead for Public Engagement with Research.